news Inhibiting protein slows glioblastoma tumour growth 11 July 2019 | By Victoria Rees (Drug Target Review) Researchers have discovered that inhibiting the ID1 protein slows the growth of glioblastoma tumours and reduces resistance to chemotherapy.
article A pragmatic approach to hit validation following biochemical high-throughput screening 12 December 2017 | By Dr Agnes Martin, Dr Laurent Rigoreau, Dr Sheila McLoughlin Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…
news Cancer Research triples funding for pancreatic cancer 20 July 2016 | By Niamh Louise Marriott, Digital Content Producer The charity increased spending on pancreatic cancer research, which includes improving diagnosis and treatment, to £18 million...
news Neurodegenerative diseases: The potential of cyclophilin inhibition 21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
news Microptosis could present an antimicrobial drug development opportunity 20 January 2016 | By Victoria White Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
news Researchers freeze EBV by disrupting the cell supply chain 20 January 2016 | By Victoria White Researchers made B-cells sense they were starving by using the drug Rapamycin, enabling them to turn the senescence of EBV-infected cells on and off...
news Regen BioPharma and NCATS to research the NR2F6 protein 20 January 2016 | By Victoria White The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
news New study finds laws of nature predict cancer evolution 19 January 2016 | By Victoria White Researchers believe that in the future, they could predict how a cancer will grow and develop by applying natural laws to single genetic snapshots taken from a cancer...
news Breast cancer study reveals new drug targets and combinations 19 January 2016 | By Victoria White The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
news UCL announces new £50 million fund to commercialise research 18 January 2016 | By Victoria White The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
news F-star and AbbVie to develop bispecific antibodies in immuno-oncology 18 January 2016 | By Victoria White Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
news Channel-blocker drug helps restore vision in mice with optic nerve injury 14 January 2016 | By Victoria White Researchers were able to restore vision in mice by using gene therapy to get the nerves to regenerate and adding a channel-blocking drug to help the nerves conduct impulses...
news Sanofi Pasteur announces support for the Human Vaccines Project 14 January 2016 | By Victoria White The Human Vaccines Project is a research programme designed to accelerate the development of vaccines by decoding the human immune system...
news Boehringer and Arena to advance research in psychiatric diseases 13 January 2016 | By Victoria White Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
news MSD acquires drug discovery company IOmet 12 January 2016 | By Victoria White The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...
